2020 Tibbetts Award Winner
ImmunogenX, LLC is pioneering eforts in Celiac disease therapy, management, and food safety. ...
You are here
Immunogenics LLC
Company Information
Information
UEI: DHJSMHJ9BJE5
# of Employees: 7
Ownership Information
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: Yes
Award Charts
Award Listing
-
A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease
Amount: $1,911,176.00The goal of this work is to evaluate the efficacy of a therapeutic agent for protecting individuals with Type 1 diabetes (T1D) and celiac disease (CD) from intestinal and symptomatic distress they suf ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease
Amount: $2,197,370.00The goal of this work is to develop a therapeutic drug that will protect individuals with celiac disease (CD) from intestinal and symptomatic distress they suffer due to minute ingestion of gluten pro ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease
Amount: $299,089.00Project Summary AbstractThe goal of this work is to develop a therapeutic drug that will protect individuals with celiac diseaseCDfrom intestinal and symptomatic distress they suffer due to minute ing ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease
Amount: $293,257.00Project Summary The goal of this work is to evaluate the efficacy of a therapeutic agent for protecting individuals with TypediabetesT Dand celiac diseaseCDfrom intestinal and symptomatic distress the ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health
